Bracco S.p.A.

Bracco Group is an Italian multinational company operating in the healthcare sector, recognized as a world leader in diagnostic imaging. Headquartered in Milan, Italy, the company's core mission is to improve people's lives by shaping the future of prevention and precision imaging. Founded in 1927, Bracco maintains a strong commitment to innovation and scientific advancement in healthcare.

The Group offers a comprehensive portfolio of products and services across three main business areas: imaging agents, medical technologies, and health services. Its key offerings include contrast agents for various diagnostic modalities such as X-ray, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), ultrasound, and nuclear medicine. Additionally, Bracco develops and markets advanced medical devices and administration systems for contrast media, and provides healthcare services through its Centro Diagnostico Italiano (CDI) in Milan.

Led by President and CEO Diana Bracco, the company continues to drive innovation, investing approximately 10% of its imaging diagnostics turnover in research and development. Recent developments include Health Canada and EU approvals for its lower-dose MRI contrast agent, gadopiclenol (VUEWAY), and the launch of AI-powered software like AiMIFY. Bracco Group is privately held and operates globally, with a presence in over 100 countries, emphasizing sustainability and strategic partnerships to advance medical imaging.